UNIQUE MOA THAT AFFECTS IL-4 AND IL-13 SIGNALING, IMPACTING TWO SOURCES THAT MEDIATE ALLERGIC AND EOSINOPHILIC INFLAMMATION

The mechanism of dupilumab action in asthma has not been established.1

Type 2 inflammation plays an important role in the pathogenesis of asthma1-3

DUPIXENT blocks the IL-4/IL-13 pathway and decreases markers of Type 2 inflammation, including1,2,4,5,a:

TOTAL AND ALLERGEN-SPECIFIC IgE Up to 70% reduction in total IgE from baseline

EOSINOPHILIC LUNG INFLAMMATION Despite the presence of normal or increased blood eosinophil levels

FeNOb (a marker of lung inflammation) Up to 35% reduction from baseline

  • aEffects based on pharmacodynamic data from Trials 1 and 2.
  • bFractional exhaled nitric oxide (FeNO) has not been established as useful for ruling in or ruling out a diagnosis of asthma; however, FeNO is higher in asthma that is characterized by Type 2 airway inflammation.7

DUPIXENT reduces inflammation in different patient populations1

The approved asthma populations may include patients who exhibit other disease characteristics, such as an allergic phenotype.

DUPIXENT IS INDICATED FOR PATIENTS (12+ YEARS) WITH MODERATE-TO-SEVERE ASTHMA WITH AN EOSINOPHILIC PHENOTYPE

Approximately 7 out of 10 asthma patients had an eosinophilic or a mixed (eosinophilic and allergic) phenotype6,c,d

  • c Overlap percentages may vary depending on the number of adults vs children, ongoing therapy, and IgE and eosinophil break points chosen.
  • d Based on a study of the general asthma population: Although not defined by clinical guidelines, eosinophilic phenotype was defined in this study as blood eosinophil count ≥150 cells/µL; allergic phenotype was defined in this study as allergen-specific IgE ≥0.35 IU/mL.

View the novel MOA in action

SEE THE VIDEO

Identify patient types appropriate for DUPIXENT

BUILD A PATIENT

References:

  1. DUPIXENT Prescribing Information.
  2. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2‑high and type 2‑low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017;47(2):161-175.
  3. Hammad H, Lambrecht BN. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nat Rev lmmunol. 2008;8(3):193-204.
  4. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
  5. Ravensberg AJ, Ricciardolo FLM, van Schadewijk A, et al. Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. J Allergy Clin Immunol. 2005;115(4):779-785.
  6. Tran TN, Zeiger RS, Peters SP, et al. Overlap of atopic, eosinophilic, and TH2-high asthma phenotypes in a general population with current asthma. Ann Allergy Asthma Immunol. 2016;116(1):37-42.
  7. Global Initiative for Asthma. Definition, description, and diagnosis of asthma. In: Global Strategy for Asthma Management and Prevention. https://ginasthma.org/. Updated 2018. Accessed February 7, 2019.